Why Is Moderna Stock Down Today?
Moderna's stock price experienced a significant decline following a record-breaking surge triggered by positive trial results for a new cancer vaccine. Investors engaged in profit-taking, despite analysts maintaining a positive long-term outlook for the company's diversification efforts.
Why it matters
The volatility reflects market sensitivity to biotech breakthroughs and the subsequent financial adjustments in the pharmaceutical sector.
Topline Moderna’s stock retreated on Thursday following a record-setting jump a day earlier, cutting more than $18 billion from the company’s market valuation, as investors appeared to pull back after the biotech giant reported breakthrough trial results for a cancer vaccine.
In this photo illustration, a smartphone displays the logo of Moderna, Inc., an American biotechnology company specializing in messenger RNA (mRNA) medicines and vaccines, in front of a screen showing the company's latest stock market chart on July 23, 2026 in Shenzhen, China. (Photo illustration by Cheng Xin/Getty Images) Getty Images Key Facts Shares of Moderna plunged more than 25% to around $129 as of early Thursday afternoon, a retreat from the firm’s record-setting 176% surge Wednesday that more than doubled the stock’s value, to above $174.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in